https://www.vipartners.ch/ https://www.vipartners.ch/about https://www.vipartners.ch/news/grid https://www.vipartners.ch/portfolio https://www.vipartners.ch/contact https://www.vipartners.ch/team https://www.vipartners.ch/team/arnd-kaltofen https://www.vipartners.ch/team/diego-braguglia https://www.vipartners.ch/team/olivier-laplace https://www.vipartners.ch/team/gaetano-zanon https://www.vipartners.ch/team/julien-pache https://www.vipartners.ch/team/gretchen-van-steenwyk https://www.vipartners.ch/team/martina-gromo https://www.vipartners.ch/team/maria-escala-garcia https://www.vipartners.ch/team/yassine-zaied https://www.vipartners.ch/team/cyrill-osterwalder https://www.vipartners.ch/team/bruno-trivelli https://www.vipartners.ch/team/irene-seebacher https://www.vipartners.ch/team/alain-nicod https://www.vipartners.ch/team/daniel-gutenberg https://www.vipartners.ch/team/susan-gasser https://www.vipartners.ch/team/elmar-schaerli https://www.vipartners.ch/portfolio/flowit https://www.vipartners.ch/portfolio/kadoa https://www.vipartners.ch/portfolio/buynomics https://www.vipartners.ch/portfolio/xo-life https://www.vipartners.ch/portfolio/oplit https://www.vipartners.ch/portfolio/leaseteq https://www.vipartners.ch/portfolio/somagenetix https://www.vipartners.ch/portfolio/vara https://www.vipartners.ch/portfolio/sibylla https://www.vipartners.ch/portfolio/skribble https://www.vipartners.ch/portfolio/almer https://www.vipartners.ch/portfolio/morgen https://www.vipartners.ch/portfolio/picterra https://www.vipartners.ch/portfolio/highlife-medical https://www.vipartners.ch/portfolio/inositec https://www.vipartners.ch/portfolio/ninox https://www.vipartners.ch/portfolio/unique https://www.vipartners.ch/portfolio/ledgy https://www.vipartners.ch/portfolio/visonys https://www.vipartners.ch/portfolio/jenavalve-technology https://www.vipartners.ch/portfolio/nexthink https://www.vipartners.ch/portfolio/mila https://www.vipartners.ch/portfolio/neocutis https://www.vipartners.ch/portfolio/kuros-biosciences https://www.vipartners.ch/portfolio/ab2-bio https://www.vipartners.ch/portfolio/altoida https://www.vipartners.ch/portfolio/acodis https://www.vipartners.ch/portfolio/oculis https://www.vipartners.ch/portfolio/araris https://www.vipartners.ch/portfolio/amal https://www.vipartners.ch/portfolio/xeltis https://www.vipartners.ch/portfolio/sumup https://www.vipartners.ch/portfolio/medlumics https://www.vipartners.ch/portfolio/merlion https://www.vipartners.ch/portfolio/ionctura https://www.vipartners.ch/portfolio/activaero https://www.vipartners.ch/portfolio/deal-united https://www.vipartners.ch/portfolio/sonicemotion https://www.vipartners.ch/portfolio/smallrivers https://www.vipartners.ch/portfolio/picodrill https://www.vipartners.ch/portfolio/nemerix https://www.vipartners.ch/portfolio/hybris-software https://www.vipartners.ch/portfolio/ir-microsystems https://www.vipartners.ch/portfolio/mesa-imaging https://www.vipartners.ch/portfolio/hpl https://www.vipartners.ch/portfolio/epispeed https://www.vipartners.ch/portfolio/avalon-photonics https://www.vipartners.ch/portfolio/xigen https://www.vipartners.ch/portfolio/sequana-medical https://www.vipartners.ch/portfolio/spinelab https://www.vipartners.ch/portfolio/ventaleon https://www.vipartners.ch/portfolio/oncalis https://www.vipartners.ch/portfolio/neogyn https://www.vipartners.ch/portfolio/thommen-medical https://www.vipartners.ch/portfolio/kuur-therapeutics https://www.vipartners.ch/portfolio/esbatech https://www.vipartners.ch/portfolio/genkyotex https://www.vipartners.ch/portfolio/endosense https://www.vipartners.ch/portfolio/endoart https://www.vipartners.ch/portfolio/ganymed https://www.vipartners.ch/portfolio/edimer https://www.vipartners.ch/portfolio/covalys https://www.vipartners.ch/portfolio/cequr https://www.vipartners.ch/portfolio/smart-valor https://www.vipartners.ch/portfolio/silentsoft https://www.vipartners.ch/portfolio/senbiosys https://www.vipartners.ch/portfolio/myotest https://www.vipartners.ch/portfolio/l.e.s.s. https://www.vipartners.ch/portfolio/gamaya https://www.vipartners.ch/portfolio/equippo https://www.vipartners.ch/portfolio/advanon https://www.vipartners.ch/news/oculis-announces-european-medicines-agency-prime-designation-for-privosegtor-advancing-a-potential-first%E2%80%91in%E2%80%91class-neuroprotective-candidate-for-optic-neuritis https://www.vipartners.ch/news/jenavalve-announces-fd-approval-of-the-trilogy-transcatheter-heart-valve-system https://www.vipartners.ch/news/reframing-saas-is-dead-in-the-era-of-intelligent-software https://www.vipartners.ch/news/vi-partners-welcomes-julien-pache-as-partner-technology https://www.vipartners.ch/news/digital-twins-in-oncology https://www.vipartners.ch/news/vi-partners-announces-first-close-of-its-new-chf-150-million-fund-reinforcing-its-long-term-commitment-to-swiss-innovation https://www.vipartners.ch/news/ionctura-initiates-phase-i-ii-trial-in-patients-with-myelofibrosis-ahead-of-new-nonclinical-data-at-ash https://www.vipartners.ch/news/xeltis-secures-nearly-%E2%82%AC50m-from-the-european-investment-bank-(eib)-and-existing-shareholders-to-advance-axess-its-vascular-access-conduit-to-the-market https://www.vipartners.ch/news/vi-partners-celebrates-the-3-billion-nexthink-valuation-a-landmark-exit-for-swiss-tech https://www.vipartners.ch/news/ionctura-debuts-cambritaxestat-(ioa-289)-clinical-data-in-patients-with-pancreatic-cancer-at-esmo https://www.vipartners.ch/news/vara-earns-ce-mark-as-the-only-ai-authorized-for-an-independent-second-read-in-mammography-and-expands-in-europe. https://www.vipartners.ch/news/unlocking-europe%E2%80%99s-ai-revolution https://www.vipartners.ch/news/oculis-accelerates-privosegtor-into-registrational-trials-in-acute-optic-neuritis-pioneering-the-path-for-a-potential-first-in-class-neuroprotective-therapy https://www.vipartners.ch/news/from-founder-s-vision-to-scalable-success https://www.vipartners.ch/news/vi-partners-strengthens-its-team-with-three-new-hires-in-healthcare-investing-and-operations https://www.vipartners.ch/news/sibylla-biotech-appoints-cso-and-vp-of-r-d-to-advance-ppi-fit-technology-and-pipeline-of-folding-interference-small-molecules https://www.vipartners.ch/news/jenavalve-announced-esc-guidelines-recognize-tavi-as-class-iib-recommendation-for-aortic-regurgitation https://www.vipartners.ch/news/ionctura-expands-roginolisib-trials-to-the-us-advancing-multi-indication-strategy-in https://www.vipartners.ch/news/oculis-upsized-loan-facility-to-access-up-to-chf-100-million https://www.vipartners.ch/news/ionctura-strengthens-medical-and-commercialization-expertise-with-two-nonexecutive-board-appointments https://www.vipartners.ch/news/xeltis-announces-positive-data-for-xabg-its-coronary-artery-bypass-conduit-in-eu-clinical-trial https://www.vipartners.ch/news/jenavalve-announces-first-patient-enrolled-in-artist-randomized-controlled-trial-(rct)-evaluating-the-trilogy%E2%84%A2-system-in-aortic-regurgitation-(ar) https://www.vipartners.ch/news/ionctura-bolsters-leadership-team-with-new-appointments https://www.vipartners.ch/news/highlife-granted-us-fda-breakthrough-device-designation-for-its-tmvr-solution https://www.vipartners.ch/news/next-generation-revenue-intelligence-software-buynomics-secures-30m-million-in-series-b-funding-to-expand-ai-driven-commercial-operating-system https://www.vipartners.ch/news/saas-veteran-and-long-time-nexthink-c-level-executive-yassine-zaied-joins-swiss-vc-vi-partners-as-operating-partner-to-accelerate-scaleups https://www.vipartners.ch/news/taiho-pharmaceutical-to-acquire-next-generation-adc-drug-discovery-company-araris-biotech https://www.vipartners.ch/news/kadoa-secures-funding-to-scale-ai-agents-for-unstructured-data https://www.vipartners.ch/news/unique-secures-usd-30-million-series-a-to-pioneer-agentic-ai-workforce-in-financial-services https://www.vipartners.ch/news/oculis-announces-pricing-of-100-million-oversubscribed-offering-of-ordinary-shares https://www.vipartners.ch/news/ab2-bio-signs-u.s.-option-and-licensing-agreement-with-nippon-shinyaku-for-tadekinig-alfa-for-an-ultra-rare-autoimmune-disease https://www.vipartners.ch/news/xeltis-announces-completion-of-enrolment-in-eu-pivotal-trial-for-axess-and-prepares-for-market-approval https://www.vipartners.ch/news/cequr-closes-a-120m-equity-financing-to-drive-commercial-growth https://www.vipartners.ch/news/oculis-announces-positive-ocs-05-phase-2-acuity-trial-in-acute-optic-neuritis-met-primary-safety-endpoint-and-key-secondary-efficacy-endpoints-opening-development-pathways-as-a-potential-first-in-class-neuroprotective-therapy https://www.vipartners.ch/news/araris-biotech-ag-announces-research-collaboration-and-option-to-license-agreement-with-chugai-pharmaceutical-co.-to-develop-next-generation-adcs-using-araris-aralinqtm-technology https://www.vipartners.ch/news/vara-s-ai-supported-mammography-revolutionizes-breast-cancer-detection-landmark-german-study-confirms-real-world-impact https://www.vipartners.ch/news/medlumics-is-proud-to-announce-the-completion-of-the-fim-study-with-successful-remapping-at-3-months-demonstrating-the-efficacy-of-the-ablaview%C3%A2%C2%AE-optically-guided-pulsed-field-ablation-(pfa)-system-and-presentation-at-the-af-symposium-2025 https://www.vipartners.ch/news/oplit-welcomes-vi-partners-as-a-new-investor-to-accelerate-its-european-expansion-and-strengthen-r-d-investments https://www.vipartners.ch/news/realwear-acquires-smartglasses-innovator-almer-to-supercharge-the-industrial-adoption-of-wearables-backed-by-teamviewer https://www.vipartners.ch/news/flowit-ag-successfully-closes-oversubscribed-first-funding-round-4-mio-chf https://www.vipartners.ch/news/market-evolution-so-far-in-2024 https://www.vipartners.ch/news/edwards-lifesciences-today-announced-investments-that-reflect-the-company%E2%80%99s-deep-commitment-to-advancing-patient-care-through-structural-heart-innovation-addressing-large-unmet-patient-needs-and-supporting-sustainable-long-term-growth. https://www.vipartners.ch/news/how-sibylla-biotech-is-using-ai-to-solve-the-problem-of-non-druggable-targets https://www.vipartners.ch/news/a-coffee-chat-with-vincent-bieri-co-founder-of-nexthink-%E2%80%93-switzerland-s-fastest-growing-saas-unicorn https://www.vipartners.ch/news/navigating-your-tech-career-a-venture-capitalist%E2%80%99s-perspective https://www.vipartners.ch/news/exploring-ai-agents-the-evolution-from-chatbots-to-intelligent-autonomous-systems https://www.vipartners.ch/news/the-most-convenient-smart-way-to-lease-any-car-anywhere---why-we-invested-in-leaseteq https://www.vipartners.ch/news/venture-capital-market-evolution-in-2023 https://www.vipartners.ch/news/vi-partners-announce-a-new-chf-8-mio.-series-a-investment-in-leaseteq https://www.vipartners.ch/news/study-published-in-nature-digital-medicine-shows-potential-predictive-power-of-augmented-reality-based-cognitive-and-functional-assessment-for-alzheimer%E2%80%99s-disease https://www.vipartners.ch/news/top-swiss-banks-embrace-genai-transformation-with-unique-financegpt https://www.vipartners.ch/news/pushing-boundaries-vi-partners-ceo-day-2023 https://www.vipartners.ch/news/araris-biotech-ag-announces-research-collaboration-with-taiho-pharmaceutical-to-develop-next-generation-adcs-using-araris%E2%80%99-proprietary-linker-conjugation-technology https://www.vipartners.ch/news/jenavalve-announces-late-breaking-data-from-the-align-ar-pivotal-trial-meeting-safety-and-efficacy-endpoints https://www.vipartners.ch/news/ninox-introduces-flexible-crm-for-smbs-based-on-low-code. https://www.vipartners.ch/news/unlocking-startup-potential-the-vi-partners-4ps-blueprint https://www.vipartners.ch/news/mid-year-review-market-evolution-in-healthtech-2023 https://www.vipartners.ch/news/xeltis-secures-additional-%E2%82%AC12.5-million-from-european-innovation-council-fund-in-final-close-of-d2-financing https://www.vipartners.ch/news/oculis-announce-positive-results-from-a-phase-3-optimize-trial-showing-that-a-daily-does-of-ocs-01-eye-drops-treats-inflammation-and-pain-following-cataract-surgery https://www.vipartners.ch/news/empowering-breast-cancer-screening-globally---why-we-invested-in-vara https://www.vipartners.ch/news/building-the-digital-healthcare-enterprise-ecosystem-%E2%80%93-customer-by-customer https://www.vipartners.ch/news/oculis-announces-positive-top-line-results-from-diamond-stage-1-phase-3-trial-in-diabetic-macular-edema-with-ocs-01-eye-drops https://www.vipartners.ch/news/manuel-grenacher-ceo-of-unique-shares-his-views-on-getting-comfortable-being-uncomfortable-and-the-power-of-company-culture. https://www.vipartners.ch/news/oculis-announces-us-public-listing-on-nasdaq https://www.vipartners.ch/news/why-did-we-invest-in-time-management-application-morgen.so https://www.vipartners.ch/news/xeltis-raises-%E2%82%AC32-million-to-drive-clinical-development-of-world%E2%80%99s-most-advanced-restorative-cardiovascular-devices https://www.vipartners.ch/news/2022-market-evolution---read-our-research-review-of-digital-healthcare-investing-in-europe https://www.vipartners.ch/news/switzerland-based-acodis-closes-chf-6-million-series-a-funding-round-to-transform-document-processing-for-pharma-and-health https://www.vipartners.ch/news/pierrick-poulenas-ceo-of-picterra-speaks-about-the-power-of-embracing-uncertainty-life-on-a-rollercoaster-and-what-to-look-for-in-an-investor. https://www.vipartners.ch/news/xeltis-starts-pivotal-clinical-trial-with-first-ever-restorative-synthetic-hemodialysis-access-graft https://www.vipartners.ch/news/vi-partners-welcomes-gaetano-zanon-as-venture-partner-technology https://www.vipartners.ch/news/sibylla-biotech-raises-%E2%82%AC23-million-series-a-to-advance-protein-degradation-by-folding-interference-pipeline-and-expand-technology-platform https://www.vipartners.ch/news/honing-the-opportunity-and-inspiration-of-venture-capital-an-interview-with-simon-meier https://www.vipartners.ch/news/10-million-for-swiss-e-signature-scale-up-skribble https://www.vipartners.ch/news/xeltis-receives-commitment-from-grand-pharma-to-invest-%E2%82%AC15m-as-cornerstone-of-ongoing-series-d2-financing-round https://www.vipartners.ch/news/morgen-raises-chf-1-million-in-pre-seed-funding-to-revolutionize-time-management https://www.vipartners.ch/news/global-fintech-sumup-raises-%E2%82%AC590-million-and-celebrates-10-years-of-supporting-small-merchants https://www.vipartners.ch/news/what-s-next-how-to-navigate-turbulent-waters https://www.vipartners.ch/news/blog-our-investment-into-ninox-and-the-rise-of-%E2%80%98low-code%E2%80%99 https://www.vipartners.ch/news/blog-satellite-images-artificial-intelligence-and-our-investment-into-geospatial-intelligence-software-picterra https://www.vipartners.ch/news/picterra-raises-6.5m-to-accelerate-its-mission-of-democratizing-geospatial-mapping https://www.vipartners.ch/news/low-code-provider-ninox-continues-to-grow-and-gains-new-investors https://www.vipartners.ch/news/blog-the-new-%E2%80%9Cremote%E2%80%9D-world-and-our-investment-into-unique https://www.vipartners.ch/news/blog-are-we-creating-a-generation-of-outliers https://www.vipartners.ch/news/unique-raises-usd-6.4-million-seed-extension-and-acquires-ciara https://www.vipartners.ch/news/sequana-medical-announces-the-completion-of-alfapump-implantations-in-poseidon-the-north-american-pivotal-alfapump-study https://www.vipartners.ch/news/altoida-upsizes-its-series-a-round-to-20.3m-to-advance-its-first-in-class-ai-powered-neurocognitive-assessment-platform https://www.vipartners.ch/news/vi-partners-strengthens-team-with-olivier-laplace-as-new-partner-for-technology-investments https://www.vipartners.ch/news/oculis-strengthens-leading-ophthalmology-pipeline-by-in-licensing-neuroprotective-drug-candidate-for-glaucoma-from-accure-therapeutics https://www.vipartners.ch/news/altoida-announces-partnership-with-click-therapeutics-to-power-clinical-trials-with-digital-cognitive-assessment https://www.vipartners.ch/news/oculis-apoints-dr.-bastian-dehmel-as-chief-development-officer https://www.vipartners.ch/news/altoida-partners-with-gn-group-to-research-and-develop-new-cognitive-assessment-technology-to-detect-mild-cognitive-impairment https://www.vipartners.ch/news/jenavalve-announces-strategic-investment-and-licensing-agreement-with-peijia-medical-limited https://www.vipartners.ch/news/oculis-appoints-mr.-webb-ding-as-global-chief-operating-officer-and-general-manager-(china) https://www.vipartners.ch/news/highlife%E2%80%99s-tsmvr-technology-successfully-used-for-the-first-time-in-china https://www.vipartners.ch/news/altoida-named-to-the-2021-cb-insights-digital-health-150----list-of-most-innovative-digital-health-startups https://www.vipartners.ch/news/sequana-medical-announces-positive-interim-results-of-sahara-desert-trial https://www.vipartners.ch/news/inositec-acquired-by-vifor-pharma-for-its-program-in-first-in-class-treatment-for-progressive-vascular-calcification https://www.vipartners.ch/news/susan-m.-gasser-advisor-to-vi-partners-receives-honorary-doctorate-by-university-of-fribourg https://www.vipartners.ch/news/oculis-announces-patient-dosing-in-its-diamond-study-diamond-its-first-phase-3-study-with-ocs-01 https://www.vipartners.ch/news/altoida-and-ionian-university-investigate-breakthrough-software-device-for-parkinson%E2%80%99s-disease-diagnosis https://www.vipartners.ch/news/araris-biotech-ag-expands-scientific-advisory-board-with-appointment-of-dr.-jeff-sharman-and-dr.-clive-stanway https://www.vipartners.ch/news/jenavalve-technology-receives-ce-mark-for-its-trilogytm-tavi-system-for-the-treatment-of-aortic-regurgitation-and-aortic-stenosis https://www.vipartners.ch/news/vi-partners-increases-their-investment-in-existing-portfolio-company-ledgy-welcoming-new-lead-investor-sequoia-capital-in-the-us-10m-series-a-round https://www.vipartners.ch/news/oculis-appoints-dr.-joanne-chang-as-global-chief-medical-officer-and-opens-hong-kong-office-to-broaden-its-footprint https://www.vipartners.ch/news/acodis-accelerates-its-growth-with-a-chf-2.5m-financing-led-by-vi-partners https://www.vipartners.ch/news/altoida-launches-5-year-multi-center-alzheimer%E2%80%99s-study-with-eisai-and-ionian-university https://www.vipartners.ch/news/altoida-awarded-fda-breakthrough-designation-for-development-of-world%E2%80%99s-first-precision-neurology-device-for-prediction-of-alzheimer%E2%80%99s-disease https://www.vipartners.ch/news/altoida-secures-funding-and-research-partnership-with-eisai-innovation-to-accelerate-work-towards-predictive-dementia-diagnostics https://www.vipartners.ch/news/xeltis-initiates-first-ever-pivotal-trial-of-a-synthetic-restorative-pulmonary-heart-valve https://www.vipartners.ch/news/merlion-pharmaceuticals-completes-growth-financing-round https://www.vipartners.ch/news/athenex-to-acquire-kuur-therapeutics-to-expand-cell-therapy-development-with-off-the-shelf-engineered-car-nkt-platform https://www.vipartners.ch/news/vi-partners-invests-in-late-stage-biopharmaceutical-company-oculis https://www.vipartners.ch/news/prof.-susan-m.-gasser-joins-vi-partners-as-advisor https://www.vipartners.ch/news/cequr-raises-115-million-series-c5-financing https://www.vipartners.ch/news/araris-appoints-chief-development-officer https://www.vipartners.ch/news/medlumics-closes-upsized-eur-18m-financing-round-and-appoints-new-chairman https://www.vipartners.ch/news/%E2%80%9Clong-on-innovation%E2%80%9D-a-conversation-with-jo%C3%ABl-mesot-president-eth-zurich https://www.vipartners.ch/news/vi-partners-invests-in-highlife-medical https://www.vipartners.ch/news/vi-partners-strengthens-team-with-joe-neale-partner-technology https://www.vipartners.ch/news/araris-biotech-completes-chf-15.2m-seed-financing-round https://www.vipartners.ch/news/sequana-medical-strong-interim-results-from-red-desert-alfapump-dsr-study-and-business-update https://www.vipartners.ch/news/vi-partners-co-leads-investment-in-medlumics%E2%80%99-%E2%82%AC14m-series-e-round https://www.vipartners.ch/news/ionctura-extends-series-a-financing-round-to-eur-20.1m https://www.vipartners.ch/news/a-new-fund-advised-by-vi-partners-made-its-first-closing-a-major-achievement-in-the-current-environment https://www.vipartners.ch/news/inositec%E2%80%99s-ins-3001-significantly-reduces-cardiovascular-calcification-in-proof-of-concept-study https://www.vipartners.ch/news/jenavalve-technology-closes-us-50m-equity-financing-led-by-bain-capital https://www.vipartners.ch/news/ionctura-raises-eur-15m-in-series-a-financing https://www.vipartners.ch/news/sequana-medical-announces-first-patient-enrolled-in-red-desert-study-for-treatment-of-diuretic-resistant-heart-failure-patients https://www.vipartners.ch/news/genkyotex-reports-progress-of-setanaxib-phase-2-investigator-initiated-trials https://www.vipartners.ch/news/jenavalve-technology-strengthens-senior-leadership-team-in-clinical-affairs-and-operations https://www.vipartners.ch/news/araris-biotech-ag-closes-seed-financing-round-of-chf-2.5m https://www.vipartners.ch/news/smart-valor-startet-handelsplattform-f%C3%BCr-krypto-assets https://www.vipartners.ch/news/gamaya-raises-chf-12m https://www.vipartners.ch/news/the-who-recognizes-nox-inhibitors-as-new-therapeutic-class-and-approves-setanaxib-for-gkt831 https://www.vipartners.ch/news/sumup-receives-a-371m-loan-to-fuel-its-expansion https://www.vipartners.ch/news/boehringer-ingelheim-acquires-amal-therapeutics https://www.vipartners.ch/news/kuros-biosciences-signs-agreement-on-distribution-of-magnetos-in-australia-and-new-zealand https://www.vipartners.ch/news/l.e.s.s.-sa-raises-chf-14m-to-accelerate-the-industrialization-of-their-products-in-the-automotive-market. https://www.vipartners.ch/news/xeltis-preclinical-data-extend-potential-of-restorative-approach-to-small-diameter-vessels https://www.vipartners.ch/news/final-data-analysis-shows-that-gkt831-demonstrated-statistically-significant-improvements-in-ggt-and-alp-over-full-treatment-period https://www.vipartners.ch/news/mahindra-picks-up-11.25-stake-in-swiss-agriculture-technology-firm-gamaya https://www.vipartners.ch/news/cequr-appoints-bradley-paddock-chief-executive-officer https://www.vipartners.ch/news/sequana-medical-announces-unconditional-fda-ide-approval-to-start-alfapump-pivotal-study-%E2%80%93-poseidon https://www.vipartners.ch/news/altoida-raises-6.3m-series-a-to-predict-alzheimer%E2%80%99s-disease-risk-using-ai-machine-learning-and-augmented-reality https://www.vipartners.ch/news/inspired-by-silicon-valley-ledgy-wants-to-help-others-give-equity-to-employees https://www.vipartners.ch/news/sequana-medical-announces-presentation-of-positive-dsr-clinical-proof-of-concept-data-demonstrating-potential-in-volume-overload-due-to-heart-failure https://www.vipartners.ch/news/amal-therapeutics-enters-clinical-collaboration-with-boehringer-ingelheim-to-evaluate-atp128-in-combination-with-bi754091 https://www.vipartners.ch/news/cell-medica-collaborators-baylor-college-of-medicine-and-texas-children%E2%80%99s-hospital-present-preclinical-data-for-an-off-the-shelf-car-nkt-therapy-platform https://www.vipartners.ch/news/cell-medica-collaborators-baylor-college-of-medicine-and-texas-children%E2%80%99s-hospital-present-positive-early-patient-data-from-car-nkt-neuroblastoma-trial https://www.vipartners.ch/news/smart-valor-lists-on-bitmax.io https://www.vipartners.ch/news/kuros-biosciences-enters-convertible-bond-financing-agreement-for-up-to-chf-5m https://www.vipartners.ch/news/kuros-biosciences-receives-us-marketing-clearance-for-intervertebral-body-fusion-device https://www.vipartners.ch/news/genkyotex-announces-completion-of-24-week-treatment-of-its-phase-2-trial-with-gkt831-in-primary-biliary-cholangitis https://www.vipartners.ch/news/cell-medica-awarded-us-8.7m-cprit-grant-to-accelerate-cmd-502-off-the-shelf-car-nkt-cell-therapy-into-clinical-development https://www.vipartners.ch/news/kuros-biosciences-signs-agreement-to-supply-seaspine-with-bone-graft-incorporating-kuros%E2%80%99s-advanced-submicron-surface-technology https://www.vipartners.ch/news/sequana-medical-raises-%E2%82%AC27.5-million-in-ipo https://www.vipartners.ch/news/sequana-medical-receives-breakthrough-device-designation-from-the-fda-for-its-alfapump%C2%AE https://www.vipartners.ch/news/data-from-multiple-studies-demonstrate-cequr-paq-basal-bolus-insulin-delivery-device-is-a-successful-alternative-to-multiple-daily-insulin-injections https://www.vipartners.ch/news/jenavalve-technology-appoints-john-t.-kilcoyne-as-chief-executive-officer https://www.vipartners.ch/news/myotest-delivers-next-generation-smart-running-features-for-smartphones-smartwatches